Abstract
Poster: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have